TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15033935
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment during exercise bouts at 35% and 60% peak oxygen consumption (VO2max)
Study: 11284814
Drug: Sevoflurane in
Normalized name: sevoflurane Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane in nitrous oxide-oxygen (2 : 1 l.min‐1)
Study: 11284814
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 1 microg.kg‐1 + propofol 2 mg.kg‐1 followed by nitrous oxide-oxygen (2 : 1 l.min‐1) and sevoflurane
Study: 11284814
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl + propofol
Study: 9307536
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of prostaglandin E2 2 mg vaginal gel
Study: 9307537
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of prostaglandin E2 (2 mg each, second dose after six hours if needed)
Study: 9307537
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of prostaglandin E2 (2 mg each)
Study: 8025745
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (BDP), 500 micrograms twice per day
Study: 17196292
Drug: Pulsed Electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Electromagnetic Field (PEMF) therapy
Study: 28777127
Drug: Individualized vibrotactile
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized vibrotactile neurofeedback training (IVNT) combined with oral medication (20 mg cinnarizine and 40 mg dimenhydrinate, three tablets per day)
Study: 26399571
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (iCBT)
Study: 26399571
Drug: Weekly check-in
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly check-in control group
Study: 25044795
Drug: Food formulations
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food formulations with unsaturated/saturated fat and beetroot extract
Study: 9058311
Drug: Subcutaneous interferon-beta
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous interferon-beta (IFN-beta) 6 million units, three times per week for 6 months
Study: 8215790
Drug: Perindopril 1
Normalized name: AMLODIPINE 10MG/PERINDOPRIL 14MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 1 mg/Kg/day for 5 months
Study: 3525237
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate (TC) 200 mg intramuscularly every 14 days for six injections
Study: 27084653
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Proton Therapy (IMPT)
Study: 27354125
Drug: Intensity Modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity Modulated Photon Therapy (IMRT)
Study: 20427546
Drug: Piperacillin-tazobactam (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin-tazobactam (4 x 4.5 g IV/day)
Study: 20427546
Drug: Carbapenem (meropenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbapenem (meropenem 3 x 1 g IV/day or imipenem 4 x 500 mg IV/day) with or without amikacin (1 g IV/day)
Study: 19667717
Drug: COX-2 selective
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: COX-2 selective inhibitors (general)
Study: 12891643
Drug: Galantamine (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16 mg per day)
Study: 12891643
Drug: Galantamine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (24 mg per day)
Study: 12891643
Drug: No cholinesterase
Normalized name: cholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: No cholinesterase therapy (control)
Study: 8768828
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg MK-677
Study: 8768828
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg MK-677
Study: 8332270
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Propranolol and Nifedipine
Study: 3298404
Drug: Acyclovir, 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir, 45 mg/kg/day by continuous intravenous infusion for 28 days
Study: 29663857
Drug: Brain training
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brain training program with weekly supervision (600 min playtime)
Study: 29663857
Drug: Passive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Passive intervention with supervision twice (offered after trial)
Study: 27716229
Drug: Ropivacaine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (20 mL of 0.375%)
Study: 27716229
Drug: Ropivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine with betamethasone (19 mL of 0.375% ropivacaine + 4 mg betamethasone)
Study: 24300220
Drug: Indomethacin submicron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin submicron particle capsules 20 mg
Study: 24300220
Drug: Indomethacin submicron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin submicron particle capsules 40 mg
Study: 20195587
Drug: Chiral method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiral method (S-ibuprofen)
Study: 20195587
Drug: Chiral method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chiral method (R-ibuprofen)
Study: 18054932
Drug: Cetrorelix (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetrorelix (0.25 mg)
Study: 10835489
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 50 mg/day
Study: 8708495
Drug: Procaterol delivered
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol delivered by metered-dose inhaler (MDI) with paper spacer
Study: 8708495
Drug: Procaterol delivered
Normalized name: procaterol
DrugBank: Procaterol (DB01366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaterol delivered by metered-dose inhaler (MDI) without spacer
Study: 1928683
Drug: Propofol anaesthetic
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anaesthetic using infusion technique
Study: 7133972
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of pirprofen
Study: 7133972
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of pirprofen
Study: 31912958
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose carbon monoxide inhalation (1.2 ml/kg for men; 1.0 ml/kg for women)
Study: 28257388
Drug: Single-shot ultrasound-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot ultrasound-guided SSNB (10 mL ropivacaine 1%)
Study: 28257388
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (ISB) (20 mL ropivacaine 0.75%)
Study: 25157767
Drug: Pemetrexed (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed (500 mg/m), Carboplatin (AUC 6), Bevacizumab (15 mg/kg) administered on day 1 of each 21-day cycle for up to six cycles, followed by maintenance pemetrexed and bevacizumab.
Study: 15044641
Drug: Dexamethasone (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.25 mg/kg IV every 12 hours for one week, then tapered)
Study: 11370826
Drug: OND 32
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OND 32 mg for the first 24 hours, followed by 8 mg every 8 hours for the following four days, combined with dexamethasone 8 mg i.v. the first day and 8 mg p.o. for the following three days.
Study: 11370826
Drug: OND 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: OND 8 mg every day for 4 days, combined with dexamethasone 8 mg i.v. and 8 mg p.o. for the following three days.
Study: 7798429
Drug: Tetracycline 500
Normalized name: oxytetracycline 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetracycline 500 mg, taken twice daily for 3 months
Study: 7798429
Drug: Tab. Gugulipid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tab. Gugulipid (equivalent to 25 mg guggulsterone), taken twice daily for 3 months
Study: 3201130
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml antacid
Study: 28742529
Drug: Empiric tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empiric tuberculosis therapy
Study: 28742529
Drug: Preventive tuberculosis
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive tuberculosis therapy
Study: 18972914
Drug: Preoperative kinesic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative kinesic treatment (K)
Study: 16554988
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg per hour SiV for 4 days
Study: 7607582
Drug: Heparin‐induced extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin‐induced extracorporeal LDL precipitation (HELP)
Study: 1555059
Drug: Calcium (1.5
Normalized name: calcium carbonate 600 mg calcium (1.5 gram) ORAL TABLET,CHEWABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1.5 g/day)
Study: 3505731
Drug: Midazolam 7.5-15.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 7.5-15.0 mg (mean elimination half-life approximately 2 h)
Study: 3505731
Drug: Brotizolam 0.125-0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brotizolam 0.125-0.25 mg (mean elimination half-life approximately 5 h)
Study: 31033786
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Lactobacillus rhamnosus) at a concentration of 5×10^9 CFU per sachet, administered twice daily by mouth.
Study: 29055531
Drug: Enzyme replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzyme replacement therapy with agalsidase alfa
Study: 11878655
Drug: Parenteral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral paracetamol
Study: 27611038
Drug: Enteral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteral paracetamol
Study: 17081535
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 50 mg from days 5‐9 of the cycle
Study: 26202922
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clomiphene citrate and metformin
Study: 15910350
Drug: Levobupivacaine 0.2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine 0.2% (group L)
Study: 10393047
Drug: Acetazolamide (AZM)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (AZM) 500 mg/d
Study: 8778430
Drug: 2.51 of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.51 of fluid (1 l normal saline and 1.51 5% dextrose)
Study: 8778430
Drug: 1 l
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 l of normal saline
Study: 8778430
Drug: Free oral
Normalized name: CariFree Oral Paste Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free oral fluids
Study: 2055080
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration via instillation into the endotracheal tube (2 mg/kg, diluted to 10 mL)
Study: 2055080
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration via bronchoscope deep endotracheally
Study: 2055080
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration via bronchoscope into the right main bronchus
Study: 2055080
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration via bronchoscope into the right lower lobe bronchus
Study: 6667814
Drug: Intravenous dl-carnitine
Normalized name: DL-CARNITINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dl-carnitine infusion
Study: 30076787
Drug: Dulaglutide once
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide once weekly
Study: 25656058
Drug: Liraglutide once
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide once daily
Study: 20628336
Drug: Platelet gels
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet gels
Study: 9809945
Drug: L-arginine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (2 x 8 g/day)
Study: 9809945
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no hemodynamically active treatment)
Study: 7484753
Drug: rTPA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTPA therapy
Study: 2702795
Drug: Metoprolol (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.07 mg/kg) followed by isoproterenol (50 micrograms/min)
Study: 2702795
Drug: Metoprolol (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (0.07 mg/kg)
Study: 368231
Drug: Sucrose electrolyte
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose electrolyte solution
Study: 31120173
Drug: Topical anti-wrinkle
Normalized name: Anti Bac Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-wrinkle cream (AM cream) only
Study: 31120173
Drug: Topical anti-wrinkle
Normalized name: Anti Bac Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anti-wrinkle cream (AM cream) and topical evening DNA repair serum (PM serum)
Study: 28533053
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine trial participants (n = 51)
Study: 26278124
Drug: Corticosteroid OMP
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid OMP (dexamethasone 2.5 mg, 5 tablets taken on 2 consecutive days weekly)
Study: 22825550
Drug: BCAA granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA granules (nocturnal administration)
Study: 22825550
Drug: BCAA granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA granules (daytime administration)
Study: 3607576
Drug: Alizapride (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alizapride (14 mg/kg)
Study: 3607576
Drug: Prochlorperazine (0.56
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prochlorperazine (0.56 mg/kg)
Study: 28303751
Drug: Bevacizumab-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-containing treatment
Study: 25881090
Drug: Probiotics administered
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics administered orally for 6 days preoperatively and 10 days postoperatively.
Study: 24078623
Drug: Postrelease planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postrelease planning for improving HIV medication adherence
Study: 24078623
Drug: Postrelease planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postrelease planning for reducing sexual and injection drug-related transmission risk
Study: 16484823
Drug: PenV 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PenV 1.5 million IU thrice daily for 20 days
Study: 16484823
Drug: PenV 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PenV 1.5 million IU thrice daily for 14 days
Study: 11345746
Drug: Milrinone (loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (loading dose of 50 micrograms.kg‐1 and continuous infusion of 0.5 microgram.kg‐1.min‐1)
Study: 11345746
Drug: Control (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (dopamine and nitroglycerine administered)
Study: 8239591
Drug: Doxycycline plus
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline plus rifampin (200 mg of doxycycline plus 600 mg of rifampin once daily for 6 weeks)
Study: 8239591
Drug: Ofloxacin plus
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ofloxacin plus rifampin (400 mg of ofloxacin plus 600 mg of rifampin once daily for 6 weeks)
Study: 25039282
Drug: VR-CP (bortezomib
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR-CP (bortezomib 1.6 mg/m², rituximab 375 mg/m², cyclophosphamide 1000 mg/m², prednisone 100 mg)
Study: 25039282
Drug: VR-CAP (bortezomib,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VR-CAP (bortezomib, rituximab, cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², prednisone)
Study: 22200806
Drug: Pamidronate (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (60 mg over 4 h in 500 ml of normal saline) administered monthly for 6 months
Study: 19879973
Drug: Sodium chenodeoxycholate
Normalized name: chenodeoxycholate
DrugBank: Chenodeoxycholic acid (DB06777)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium chenodeoxycholate (CDC) 500 mg or 1000 mg, given for 4 days
Study: 19879973
Drug: Colesevelam (1.875
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam (1.875 g, twice daily)
Study: 18052925
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil meal (31 g of mixed fat and 9 g of fish oil)
Study: 18052925
Drug: Placebo oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oil meal (40 g of mixed fat)
Study: 12587957
Drug: Colon-targeted tablet-20
Normalized name: COLON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon-targeted tablet-20
Study: 12587957
Drug: Colon-targeted tablet-30
Normalized name: COLON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colon-targeted tablet-30
Study: 12587957
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release capsules
Study: 9598887
Drug: Azathioprine (AZA)
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine (AZA) 1 mg/kg/day for 6 months
Study: 29129174
Drug: High concentration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentration oxygen therapy (delivered via Hudson mask at 8 L/min, without regard to Spo2)
Study: 29129174
Drug: Titrated oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oxygen therapy (oxygen delivered via nasal prongs to achieve peripheral oxygen saturation [Spo2] of 88‐92%)
Study: 17013922
Drug: Piribedil (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piribedil (150-300 mg/day)
Study: 15233676
Drug: Tegaserod (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod (both doses)
Study: 9296407
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg I.V. dolasetron
Study: 9296407
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg I.V. dolasetron
Study: 9296407
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg I.V. dolasetron
Study: 9296407
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg I.V. dolasetron
Study: 30361335
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control for glycemic control)
Study: 30361335
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (control for BP control)
Study: 27538108
Drug: Skin needling
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skin needling plus silicone gel (Group A)
Study: 27538108
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel plus skin needling (Group B)
Study: 27538108
Drug: Silicone gel
Normalized name: SILTREX Silicone Gel-Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone gel (Control for Group B)
Study: 19880501
Drug: Thalidomide 200
Normalized name: thalidomide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 200 mg orally, days 1 to 28 plus adriamycin and dexamethasone
Study: 19880501
Drug: Thalidomide 50
Normalized name: thalidomide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide 50 mg daily (maintenance)
Study: 17675321
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nebulised rhDNase
Study: 17675321
Drug: Oxygen supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen supplementation and bronchodilator treatments
Study: 17142512
Drug: Cold-adapted influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold-adapted influenza vaccine-trivalent
Study: 12576620
Drug: Erythromycin treatment
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erythromycin treatment for chancroid
Study: 12576620
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose regimens for H ducreyi infection
Study: 8678100
Drug: Cefepime high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime high-dose
Study: 4008115
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ketotifen + 300 mg theophylline
Study: 4008115
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ketotifen + 600 mg theophylline
Study: 4008115
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg ketotifen
Study: 4008115
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg theophylline
Study: 22946072
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy‐based guided self‐management intervention adapted for Maori
Study: 12005116
Drug: Sodium lauryl
Normalized name: sodium lauryl sulfate
DrugBank: Sodium lauryl sulfate (DB00815)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium lauryl sulphate (SLS) 0.25% and 0.5% patch test